{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:42:07Z","timestamp":1776170527540,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s10157-023-02322-4","type":"journal-article","created":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T12:02:53Z","timestamp":1675512173000},"page":"358-364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Design and methods of an open-label, randomized controlled trial to evaluate the effect of pemafibrate on proteinuria in CKD patients (PROFIT-CKD)"],"prefix":"10.1007","volume":"27","clinical-trial-number":[{"clinical-trial-number":"umin000042284","registry":"10.18810\/umin-japan"}],"author":[{"given":"Mai","family":"Seki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9235-5615","authenticated-orcid":false,"given":"Toshiaki","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Matsukuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouta","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Ohkuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanari","family":"Kitazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,4]]},"reference":[{"issue":"4","key":"2322_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.5551\/jat.10454","volume":"19","author":"T Shoji","year":"2012","unstructured":"Shoji T, Abe T, Matsuo H, Egusa G, Yamasaki Y, Kashihara N, et al. Chronic kidney disease, dyslipidemia, and atherosclerosis. J Atheroscler Thromb. 2012;19(4):299\u2013315. https:\/\/doi.org\/10.5551\/jat.10454.","journal-title":"J Atheroscler Thromb"},{"issue":"2","key":"2322_CR2","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1681\/asn.2004080656","volume":"16","author":"P Muntner","year":"2005","unstructured":"Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Neprhol. 2005;16(2):529\u201338. https:\/\/doi.org\/10.1681\/asn.2004080656.","journal-title":"J Am Soc Neprhol"},{"issue":"5","key":"2322_CR3","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.2337\/diacare.26.5.1402","volume":"26","author":"GB Appel","year":"2003","unstructured":"Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar-Jimenez F, Campos MM, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care. 2003;26(5):1402\u20137. https:\/\/doi.org\/10.2337\/diacare.26.5.1402.","journal-title":"Diabetes Care"},{"issue":"9","key":"2322_CR4","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1093\/ndt\/12.9.1908","volume":"12","author":"O Samuelsson","year":"1997","unstructured":"Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant. 1997;12(9):1908\u201315. https:\/\/doi.org\/10.1093\/ndt\/12.9.1908.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"2322_CR5","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1681\/asn.2006010012","volume":"17","author":"S Sandhu","year":"2006","unstructured":"Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17(7):2006\u201316. https:\/\/doi.org\/10.1681\/asn.2006010012.","journal-title":"J Am Soc Nephrol"},{"issue":"7645","key":"2322_CR6","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1136\/bmj.39472.580984.AE","volume":"336","author":"GF Strippoli","year":"2008","unstructured":"Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336(7645):645\u201351. https:\/\/doi.org\/10.1136\/bmj.39472.580984.AE.","journal-title":"BMJ"},{"issue":"4","key":"2322_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10157-020-02000-9","volume":"25","author":"T Nakano","year":"2021","unstructured":"Nakano T, Tanaka S, Tsuruya K, Kitazono T. Relationship between serum lipid concentrations and impaired renal function in patients with chronic kidney disease: the Fukuoka Kidney Disease Registry Study. Clin Exp Neprhol. 2021;25(4):385\u201393. https:\/\/doi.org\/10.1007\/s10157-020-02000-9.","journal-title":"Clin Exp Neprhol"},{"issue":"6","key":"2322_CR8","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.ajkd.2018.11.010","volume":"73","author":"A Bajaj","year":"2019","unstructured":"Bajaj A, Xie D, Cedillo-Couvert E, Charleston J, Chen J, Deo R, et al. Lipids, apolipoproteins, and risk of atherosclerotic cardiovascular disease in persons with CKD. Am J Kidney Dis. 2019;73(6):827\u201336. https:\/\/doi.org\/10.1053\/j.ajkd.2018.11.010.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2322_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.5551\/jat.44412","volume":"25","author":"H Arai","year":"2018","unstructured":"Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S. Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, placebo-controlled, double-blind. Randomized Trial J Atheroscler Thromb. 2018;25(6):521\u201338. https:\/\/doi.org\/10.5551\/jat.44412.","journal-title":"Randomized Trial J Atheroscler Thromb"},{"issue":"1","key":"2322_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","volume":"12","author":"S Ishibashi","year":"2018","unstructured":"Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol. 2018;12(1):173\u201384. https:\/\/doi.org\/10.1016\/j.jacl.2017.10.006.","journal-title":"J Clin Lipidol"},{"key":"2322_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030706","author":"K Yokote","year":"2019","unstructured":"Yokote K, Yamashita S, Arai H, Araki E, Suganami H, Ishibashi S, et al. Long-term efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor-\u03b1 modulator (SPPARM\u03b1), in dyslipidemic patients with renal impairment. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20030706.","journal-title":"Int J Mol Sci"},{"key":"2322_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.metabol.2017.02.013","volume":"71","author":"T Maki","year":"2017","unstructured":"Maki T, Maeda Y, Sonoda N, Makimura H, Kimura S, Maeno S, et al. Renoprotective effect of a novel selective PPAR\u03b1 modulator K-877 in db\/db mice: a role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway. Metabolism. 2017;71:33\u201345. https:\/\/doi.org\/10.1016\/j.metabol.2017.02.013.","journal-title":"Metabolism"},{"issue":"2","key":"2322_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s13730-020-00444-2","volume":"9","author":"A Tanaka","year":"2020","unstructured":"Tanaka A, Nakamura T, Sato E, Chihara A, Node K. Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARM\u03b1), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia. CEN Case Rep. 2020;9(2):141\u20136. https:\/\/doi.org\/10.1007\/s13730-020-00444-2.","journal-title":"CEN Case Rep"},{"issue":"3","key":"2322_CR14","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2337\/dc17-1589","volume":"41","author":"E Araki","year":"2018","unstructured":"Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, et al. Effects of pemafibrate, a novel selective PPAR\u03b1 modulator, on lipid and glucose metabolism in patients with Type 2 Diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2018;41(3):538\u201346. https:\/\/doi.org\/10.2337\/dc17-1589.","journal-title":"Diabetes Care"},{"issue":"5","key":"2322_CR15","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jacl.2018.06.010","volume":"12","author":"S Yamashita","year":"2018","unstructured":"Yamashita S, Arai H, Yokote K, Araki E, Suganami H, Ishibashi S. Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia. J Clin Lipidol. 2018;12(5):1267\u201379. https:\/\/doi.org\/10.1016\/j.jacl.2018.06.010.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"2322_CR16","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1080\/0886022x.2018.1535983","volume":"40","author":"A Masajtis-Zagajewska","year":"2018","unstructured":"Masajtis-Zagajewska A, Nowicki M. Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease - a randomized double blind crossover study. Ren Fail. 2018;40(1):700\u20139. https:\/\/doi.org\/10.1080\/0886022x.2018.1535983.","journal-title":"Ren Fail"},{"issue":"3","key":"2322_CR17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/jdi.12296","volume":"6","author":"A Takazakura","year":"2015","unstructured":"Takazakura A, Sakurai M, Bando Y, Misu H, Takeshita Y, Kita Y, et al. Renoprotective effects of atorvastatin compared with pravastatin on progression of early diabetic nephropathy. J Diabetes Investig. 2015;6(3):346\u201353. https:\/\/doi.org\/10.1111\/jdi.12296.","journal-title":"J Diabetes Investig"},{"issue":"9","key":"2322_CR18","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1161\/circulationaha.113.002529","volume":"129","author":"FM Sacks","year":"2014","unstructured":"Sacks FM, Hermans MP, Fioretto P, Valensi P, Davis T, Horton E, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation. 2014;129(9):999\u20131008. https:\/\/doi.org\/10.1161\/circulationaha.113.002529.","journal-title":"Circulation"},{"issue":"2","key":"2322_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/sj.ki.5002017","volume":"71","author":"K Yamagata","year":"2007","unstructured":"Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71(2):159\u201366. https:\/\/doi.org\/10.1038\/sj.ki.5002017.","journal-title":"Kidney Int"},{"issue":"9500","key":"2322_CR20","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/s0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849\u201361. https:\/\/doi.org\/10.1016\/s0140-6736(05)67667-2.","journal-title":"Lancet"},{"issue":"3","key":"2322_CR21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1053\/j.ajkd.2004.11.004","volume":"45","author":"JC Ansquer","year":"2005","unstructured":"Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis. 2005;45(3):485\u201393. https:\/\/doi.org\/10.1053\/j.ajkd.2004.11.004.","journal-title":"Am J Kidney Dis"},{"key":"2322_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/nu11071664","author":"H Nishi","year":"2019","unstructured":"Nishi H, Higashihara T, Inagi R. Lipotoxicity in kidney, heart, and skeletal muscle dysfunction. Nutrients. 2019. https:\/\/doi.org\/10.3390\/nu11071664.","journal-title":"Nutrients"},{"issue":"9731","key":"2322_CR23","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/s0140-6736(10)60674-5","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073\u201381. https:\/\/doi.org\/10.1016\/s0140-6736(10)60674-5.","journal-title":"Lancet"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-023-02322-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-023-02322-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-023-02322-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T01:02:10Z","timestamp":1679878930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-023-02322-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["2322"],"URL":"https:\/\/doi.org\/10.1007\/s10157-023-02322-4","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,4]]},"assertion":[{"value":"25 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have declared no competing interest. The drug pemafibrate used in this study is manufactured and sold by Kowa Co., Ltd. There is no conflict of interest between us and Kowa Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study follows \u201cDeclaration of Helsinki\u201d, the current version adopted in 64th World Medical Association Fortaleza General Assembly Revised Edition, \u201cEthical guidelines for medical and health research involving human subjects\u201d from the Japanese Ministry of Health, Labour and Welfare in 2014 at first, and \u201cEthical guidelines for medical and biological research involving human subjects\u201d from the Japanese Ministry of Health, Labour and Welfare in 2022 from April 2022. And this study was approved by the Institutional Review Board of Kyushu University (approval number 20202015).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}